US clinical-stage biotech Spyre Therapeutics on Wednesday announced the closing of its previously announced underwritten public offering of 17,094,594 shares of its common stock, including the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback